For the Inventor, By the Inventor

Enter assignee name

High Wycombe, United Kingdom

Respivert Limited

USPTO Granted Patents = 63

EPO Patents = 31

Forward Citations = 642

Loading Chart...

Loading Chart...

52 inventors (with patents filed for the assignee):

John King-Underwood (38 out of 39 patents)

Stuart Thomas Onions (37 out of 65 patents)

Kazuhiro Ito (27 out of 49 patents)

4. Peter John Murray (23 out of 38 patents)

5. Catherine Elisabeth Charron (21 out of 21 patents)

6. Alistair Ian Longshaw (18 out of 20 patents)

7. Jonathan Gareth Williams (17 out of 18 patents)

8. Matthew Colin Thor Fyfe (15 out of 23 patents)

9. Peter Strong (11 out of 38 patents)

10. William Garth Rapeport (11 out of 11 patents)

11. Stephen Thom (11 out of 60 patents)

12. Euan Alexander Fraser Fordyce (9 out of 20 patents)

13. George Hardy (8 out of 8 patents)

14. Alex Herman Copmans (8 out of 14 patents)

15. Jennifer Diane Venable (8 out of 51 patents)

Core Competencies:

P38 MAP Kinase Inhibitors

Protein Kinase Inhibitors

Pyrazolyl-Ureas

Indole Derivatives

Quinazolin-4(3H)-One Derivatives

Fibrotic Diseases

Respiratory Formulations

Urea Derivatives

Phosphoinositide 3-Kinase Inhibitors

N-Alkyl Pyrazoles

Indolinones Compounds

Kinase Inhibitors

63 patents: Sort by Forward Citations

1. 11634406 - Inhibitor of p38 MAP kinase (2023-04-25),

2. 11208381 - Indole derivatives and their use as protein kinase inhibitors (2021-12-28),

3. 11142515 - Pyrazolyl-ureas as kinase inhibitors (2021-10-12),

4. 11046672 - Indolinones compounds and their use in the treatment of fibrotic diseases (2021-06-29),

5. 10815217 - Inhibitor of p38 MAP kinase (2020-10-27),

6. 10813932 - 1-pyrazolyl-3-(4-((2-anilinopyrimidin-4-yl) oxy) napththalen-1-yl) ureas as P38 MAP knase inhibitors (2020-10-27),

7. 10738032 - 1-pyrazolyl-3-(4-((2-anilinopyrimidin-4-yl) oxy) napththalen-i-yl) ureas as P38 mapkinase inhibitors (2020-08-11),

8. 10669235 - Indole derivatives and their use as protein kinase inhibitors (2020-06-02),

9. 10358445 - Respiratory formulations and compounds for use therein (2019-07-23),

10. 10294216 - Pyrazolyl ureas as kinase inhibitors (2019-05-21),

11. 10266519 - 1-pyrazolyl-3-(4-((2-anilinopyrimidin-4-yl) oxy) napththalen-I-yl) ureas as P38 mapkinase inhibitors (2019-04-23),

12. 10238658 - 1-pyrazolyl-3-(4-((2-anilinopyrimidin-4-yl) oxy) napththalen-1-yl) ureas as p38 MAP kinase inhibitors (2019-03-26),

13. 10144721 - P38 MAP kinase inhibitors (2018-12-04),

14. 10125100 - Kinase inhibitors (2018-11-13),

15. 10072034 - Kinase inhibitors (2018-09-11),

Respivert Limited is a biopharmaceutical company dedicated to the discovery and development of novel therapeutics for respiratory diseases. Our team of researchers and scientists work tirelessly to advance treatment options for conditions such as asthma, chronic obstructive pulmonary disease (COPD), and rare lung disorders. With a focus on delivering innovative solutions, we aim to enhance the lives of patients worldwide. Visit our website for more information about our cutting-edge research and development initiatives.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Dec 30 2025

63 Patents

#1 in High Wycombe

#283 in United Kingdom

#11,205 in the World

High Wycombe, United Kingdom

Respivert Limited

Forward Citations = 642

52 inventors:

John King-Underwood (38 out of 39 patents)

Stuart Thomas Onions (37 out of 65 patents)

Kazuhiro Ito (27 out of 49 patents)

4. Peter John Murray (23 out of 38 patents)

5. Catherine Elisabeth Charron (21 out of 21 patents)

Please report any incorrect information to support@idiyas.com

Loading…